A daily pill is usually determined for the evening Arthritis And may also be alopecia Slow progress Of Type 1 diabetes,
Chronic Disease, Due to Immune system Forbidden Insulin-producing cells In the pancreas, affects about 270,000 people living in England and many have to be taken Life insulin injection To help manage their blood sugar levels.
But found in two -year Australian test Medicine Baricitinib – that works by blocking signs that lead to overacity of the immune system – in those people help protect the remaining insulin -producing cells that are new diagnoses.
Researchers believe that this drug, which is already used to treat many autoimmune diseases, can delay the progression of symptoms of type 1 diabetes.
Dr. of the Institute of Medical Research of St. Vincent in Fijoy, Australia. Micharia Webel said: “For the first time, we have an oral disease-propelled treatment that can make people with type 1 diabetes to make sufficient interfering with much less dependent on insulin treatment and can provide free time from the demands of daily management of the disease, and which may also be short for long periods.”
The first test in 2023 nominated 91 people, who had recently diagnosed type 1 diabetes within the last 100 days. Participants were given either a barisitinib pill (4mg) or a placebo once daily for 48 weeks.
Participants C -Peptide level – A marker of insulin secretions – to find out how much insulin participants can make themselves and also monitored their glucose monitoring and HBA 1C to check their blood sugar levels.
Researchers found that Barisitinib, which preserved insulin-producing cells, reduced blood sugar fluctuations, and reduced the requirement of insulin.
Now a follow -up test results have been revealed European Union for Diabetes Studies In Vienna, which suggests that once the drug was stopped, the diabetes of the participants has progressed.
Researchers found in 48 weeks that the C-Peptide level was 0.65 in the Barisitinib group and 0.43 in the placebo group. After stopping the treatment, the C-Peptide levels in the Barisitinib group 0.49 NMOL per liter and in the placebo group in 0.36 72 weeks, and then reduced to 96 weeks by 0.37 and 0.26 respectively, performing low insulin production.
When Barisitinib treatment was stopped, participants required more insulin treatment with requirements in the week 72 and 96 that were not quite different for the Placebo group.
No additional safety concerns have been raised in the follow -up period and researchers hope that drug may be available for diabetes over the next five years.
“If we can identify people with high risk development of type 1 diabetes with genetic tests and blood markers, then they can also be offered treatment before so that the disease can be caught in the first place.”
“We hope that the larger phase III tests with Barisitinib are going to start soon, in the recently diagnosed type 1 diabetes with diabetes -in the earlier stages to delay insulin dependence.”